Vascular normalization in Rgs5-deficient tumours promotes immune destruction

Juliana Hamzah, M. Jugold, F. Kiessling, Paul Rigby, Mitali Manzur, H.H. Marti, T. Rabie, S. Kaden, H-J. Grone, G.J. Hammerling, A. Bernd, Ruth Ganss

Research output: Contribution to journalArticlepeer-review

465 Citations (Scopus)

Abstract

The vasculature of solid tumours is morphologically aberrant and characterized by dilated and fragile vessels, intensive vessel sprouting and loss of hierarchical architecture(1). Constant vessel remodelling leads to spontaneous haemorrhages(2) and increased interstitial fluid pressure in the tumour environment(3,4). Tumour-related angiogenesis supports tumour growth and is also a major obstacle for successful immune therapy as it prevents migration of immune effector cells into established tumour parenchyma(2,5,6). The molecular mechanisms for these angiogenic alterations are largely unknown. Here we identify regulator of G-protein signalling 5 (Rgs5) as a master gene responsible for the abnormal tumour vascular morphology in mice. Loss of Rgs5 results in pericyte maturation, vascular normalization and consequent marked reductions in tumour hypoxia and vessel leakiness. These vascular and intratumoral changes enhance influx of immune effector cells into tumour parenchyma and markedly prolong survival of tumour-bearing mice. This is the first demonstration, to our knowledge, of reduced tumour angiogenesis and improved immune therapeutic outcome on loss of a vascular gene function and establishes a previously unrecognized role of G-protein signalling in tumour angiogenesis.
Original languageEnglish
Pages (from-to)410-414
JournalNature
Volume453
Issue number15
DOIs
Publication statusPublished - 2008

Fingerprint

Dive into the research topics of 'Vascular normalization in Rgs5-deficient tumours promotes immune destruction'. Together they form a unique fingerprint.

Cite this